Mikel P. Moyer

6.5k citations

28 papers · 2.5k indexed · 2 hit papers · h-index 19

Molecular Biology top 5%
- Epigenetics and DNA Methylation 19
- Cancer-related gene regulation 18
- RNA modifications and cancer 6
Hematology top 5%
- Acute Myeloid Leukemia Research 5
Organic Chemistry top 5%
- Synthesis and biological activity 2
- Synthesis and Characterization of Heterocyclic Compounds 2
Cancer Research
Pathology and Forensic Medicine top 10%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 2
Pharmaceutical Science
- Chemical Reactions and Isotopes 2

Co-authors: Margaret Porter Scott Robert A. Copeland Roy M. Pollock Richard Chesworth Victoria M. Richon Alejandra Raimondi Christine R. Klaus Tim J. Wigle
Cited by: Molecular Biology Hematology Organic Chemistry
Journals: Proceedings of the National Academy of Sciences (1 paper)Blood (5 papers)PLoS ONE (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mikel P. Moyer

28 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mikel P. Moyer

Since Specialization

Citations

This map shows the geographic impact of Mikel P. Moyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikel P. Moyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikel P. Moyer more than expected).

Fields of papers citing papers by Mikel P. Moyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikel P. Moyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikel P. Moyer. The network helps show where Mikel P. Moyer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mikel P. Moyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mikel P. Moyer Line = papers co-authored together Mikel P. Moyer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,James O’Neill,Marie-Ève Rodrigue,Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	2015	23
2	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening SLAS DISCOVERY ·Tim J. Wigle,Kerren K. Swinger,John E. Campbell,Michael D. Scholle,John Sherrill,Elizabeth A. Admirand,P. Ann Boriack‐Sjodin,Kevin W. Kuntz,Richard Chesworth,Mikel P. Moyer,Margaret Porter Scott,Robert A. Copeland	2015	31
3	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652 Drug Metabolism and Disposition ·Nathalie Rioux,Lorna H. Mitchell,Philip R. Tiller,Katie Plant,J.P. Shaw,Kerry Frost,Scott Ribich,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	2015	5
4	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor Xenobiotica ·Nathalie Rioux,Kenneth W. Duncan,Ronald J. Lantz,Xiu‐Sheng Miao,Elayne Chan-Penebre,Mikel P. Moyer,Michael J. Munchhof,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	2015	16
5	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound ACS Medicinal Chemistry Letters ·Lorna H. Mitchell,Allison E. Drew,Scott Ribich,Nathalie Rioux,Kerren K. Swinger,Suzanne L. Jacques,Trupti Lingaraj,P. Ann Boriack‐Sjodin,Nigel J. Waters,Tim J. Wigle,Oscar Moradei,Lei Jin,Thomas V. Riera,Margaret Porter-Scott,Mikel P. Moyer,J. Joshua Smith,Richard Chesworth,Robert A. Copeland	2015	95
6	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 ACS Medicinal Chemistry Letters ·Kenneth W. Duncan,Nathalie Rioux,P. Ann Boriack‐Sjodin,Michael J. Munchhof,Lawrence A. Reiter,Christina R. Majer,Lei Jin,L. Danielle Johnston,Elayne Chan-Penebre,Kristy G. Kuplast,Margaret Porter Scott,Roy M. Pollock,Nigel J. Waters,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth	2015	103
7	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity ACS Medicinal Chemistry Letters ·John E. Campbell,Kevin W. Kuntz,Sarah K. Knutson,Natalie M. Warholic,Heike Keilhack,Tim J. Wigle,Alejandra Raimondi,Christine R. Klaus,Nathalie Rioux,Akira Yokoi,Satoshi Kawano,Yukinori Minoshima,Hyeong-Wook Choi,Margaret Porter Scott,Nigel J. Waters,J. Joshua Smith,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland	2015	94
8	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells Journal of Pharmacology and Experimental Therapeutics ·Christine R. Klaus,Dorothy Iwanowicz,Danielle Johnston,Carly A. Campbell,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott,Roy M. Pollock,Scott R. Daigle,Alejandra Raimondi	2014	96
9	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS ONE ·Sarah K. Knutson,Natalie M. Warholic,L. Danielle Johnston,Christine R. Klaus,Tim J. Wigle,Dorothy Iwanowicz,Bruce A. Littlefield,Margaret Porter-Scott,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Roy M. Pollock,Kevin W. Kuntz,Alejandra Raimondi,Heike Keilhack	2014	55
10	Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor Biopharmaceutics & Drug Disposition ·Aravind Basavapathruni,Edward J. Olhava,Scott R. Daigle,Carly A. Therkelsen,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Angelos Dovletoglou,Victoria M. Richon,Roy M. Pollock,Robert A. Copeland,Mikel P. Moyer,Richard Chesworth,Paul G. Pearson,Nigel J. Waters	2014	64
11	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → Blood ·Scott R. Daigle,Edward J. Olhava,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	2013	546
12	Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys27 methylation by human polycomb repressive complex 2 and vSET Biochemical Journal ·Brooke M. Swalm,Kenneth K. Hallenbeck,Christina R. Majer,Lei Jin,Margaret Porter Scott,Mikel P. Moyer,Robert A. Copeland,Tim J. Wigle	2013	5
13	EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models Blood ·L. Danielle Johnston,Sarah K. Knutson,Natalie M. Warholic,Christine R. Klaus,Tim J. Wigle,Dorothy Iwanowicz,Bruce A. Littlefield,Margaret Porter Scott,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Roy M. Pollock,Kevin W. Kuntz,Heike Keilhack,Alejandra Raimondi	2013	5
14	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients FEBS Letters ·Christina R. Majer,Lei Jin,Margaret Porter Scott,Sarah K. Knutson,Kevin W. Kuntz,Heike Keilhack,J. Joshua Smith,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Tim J. Wigle	2012	116
15	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,Carly A. Therkelsen,Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	2012	114
16	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. Blood ·Roy M. Pollock,Scott R. Daigle,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Edward J. Olhava	2012	3
17	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis Analytical Biochemistry ·Robert A. Copeland,Aravind Basavapathruni,Mikel P. Moyer,Margaret Porter Scott	2011	82
18	Structure-activity relationships of imidazo[4,5-f]quinoline partial structures and analogs. Discovery of pyrazolo[3,4-f]quinoline derivatives as potent immunostimulants Journal of Medicinal Chemistry ·Mikel P. Moyer,Frederick Weber,Jonathan Groß	1992	20
19	Metal-halogen exchange of bromoindoles. A route to substituted indoles The Journal of Organic Chemistry ·Mikel P. Moyer,John F. Shiurba,Henry Rapoport	1986	115
20	Intramolecular nitrogen-hydrogen, oxygen-hydrogen and sulfur-hydrogen insertion reactions. Synthesis of heterocycles from .alpha.-diazo .beta.-keto esters The Journal of Organic Chemistry ·Mikel P. Moyer,Paul L. Feldman,Henry Rapoport	1985	130

About Mikel P. Moyer

Mikel P. Moyer is a scholar working on Hematology, Molecular Biology and Pharmaceutical Science, having authored 28 papers that have together received 2.5k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (19 papers), Cancer-related gene regulation (18 papers), RNA modifications and cancer (6 papers), Acute Myeloid Leukemia Research (5 papers), Synthesis and biological activity (2 papers), Synthesis and Characterization of Heterocyclic Compounds (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Chemical Reactions and Isotopes (2 papers). The work is most often cited by research in Molecular Biology (2.1k citations), Hematology (267 citations) and Organic Chemistry (371 citations). Mikel P. Moyer has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Margaret Porter Scott, Robert A. Copeland, Roy M. Pollock, Richard Chesworth, Victoria M. Richon, Alejandra Raimondi, Christine R. Klaus, Tim J. Wigle, Christina J. Allain and Kevin W. Kuntz. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact